Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Duncan McKechnie

At a glance: Duncan McKechnie is Evp, Chief Commercial Officer at Vertex Pharmaceuticals (VRTX). Their latest SEC Form 4, filed Jul 7, 2026, reported a sale of $800K. On file: 0 purchase lines ($0) and 5 sale lines ($5.7M).

Disclosed holdings: about $5.7M of VRTX stock: 11,001 shares reported on their latest Form 4 (filed Jul 7, 2026), valued at the Nov 19, 2026 close of $521.30. This counts only VRTX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Evp, Chief Commercial Officer at Vertex Pharmaceuticals Inc / Ma (VRTX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $5.7M

Duncan McKechnie's InsiderPrint

5 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.

InsiderPrint of Duncan McKechnie: 5 trades, 2026 to 20262026: 0 buys, 5 sales

Reading this print: Almost only sells, trading about 5 times a year, typically $1.2M a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (0)
  • Dent inward: a sale (5)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Joseph LoscalzoDirector · IONS · 100% match
  2. Justin PetersonCTO · TW · 100% match
  3. Kathryn M. HorganPresident · STT · 100% match
  4. Robert BarrowCEO · DFTX · 99% match
  5. Michael L. MoehnCFO · AEE · 99% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Jul 7SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 1,54111,001 held (−12%) $519.00 $800K +0.4%
Mar 13SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,63312,489 held (−17%) $498.42 $1.3M +4.6%
Mar 6SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,43715,122 held (−14%) $475.30 $1.2M +9.7%
Feb 26SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,50019,969 held (−11%) $486.35 $1.2M +7.2%
Feb 26SEC VRTXVertex Pharmaceuticals Inc / Ma Sell Plan 2,41017,559 held (−12%) $489.00 $1.2M +6.6%
  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $800K of VRTX at $519.00 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $1.3M of VRTX at $498.42 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $1.2M of VRTX at $475.30 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $1.2M of VRTX at $486.35 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Evp, Chief Commercial Officer Duncan Mckechnie sold $1.2M of VRTX at $489.00 — pre-scheduled 10b5-1 plan sale.

Follow Duncan McKechnie

Get one email when Duncan McKechnie files a new purchase or sale. Free.

At most one email a day about Duncan McKechnie, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.